Carboplatin: a clinical review.
Carboplatin is a platinum analog that is less nephrotoxic, less neurotoxic, and less emetic than cisplatin, but has a similar spectrum of antitumor activity. Myelotoxicity is dose limiting. Carboplatin offers several advantages over cisplatin, in addition to a better quality of life. It may be useful in ABMT in refractory germ cell cancers in combination with etoposide. It may also prove useful in patients who have impaired renal function but require a drug with the efficacy of cisplatin.
Yarbro
C H
CH
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin; D006801:Humans; D009859:Oncology Nursing; D009944:Organoplatinum Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin